Position in AMGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$863,294
-$10,344,226 QoQ
Shares Held
2,384
-94.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.57%
of 13F equity value
Holder Rank
#1,798
of 3,149 holders
Holding Since
Mar 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AMGN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bayesian Capital Management, LP holds $5,153,335 across 7 Drug Manufacturers - General names. AMGN ranks #4 (16.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
9,100 | $1,149,694 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
19,200 | $1,106,304 | |
| 3 | GSK |
GSK plc
|
18,100 | $948,802 | |
| 4 | AMGN |
Amgen Inc
This page
|
2,384 | $863,294 | |
| 5 | NVO |
Novo Nordisk A S
|
8,500 | $407,490 | |
| 6 | NVS |
Novartis AG
|
2,365 | $370,642 | |
| 7 | SNY |
Sanofi
|
7,199 | $307,109 |
All Filings in AMGN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $863,294 | 2,384 | Shares | Sole | 2026-08-14 | |
| 2024-12-31 | $11,207,520 | 43,000 | Shares | Sole | 2025-02-14 | |
| 2024-06-30 | $3,756,273 | 12,022 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $2,081,791 | 7,322 | Shares | Sole | 2024-05-15 | |
| 2023-09-30 | $4,407,664 | 16,400 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $4,085,168 | 18,400 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $1,184,575 | 4,900 | Shares | Sole | 2023-05-15 | |
| 2022-03-31 | $1,039,826 | 4,300 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||